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Neuroblastoma cell culturesBeta-site APP cleaving enzyme 1 (BACE1) is the rate limiting enzyme for accumulation of amyloid β (Aβ)-
peptide in the brain in Alzheimer's disease (AD). Oxidative stress (OS) that leads to metabolic dysfunction
and apoptosis of neurons in AD enhances BACE1 expression and activity. The activation of c-jun N-terminal
kinase (JNK) pathway was proposed to explain the BACE1 mRNA increase under OS. However, little is
known about the translational control of BACE1 in OS. Recently, a post-transcriptional increase of BACE1
level controlled by phosphorylation of eIF2α (eukaryotic translation initiation factor-2α) have been de-
scribed after energy deprivation. PKR (double-stranded RNA dependant protein kinase) is a pro-apoptotic ki-
nase that phosphorylates eIF2α andmodulates JNK activation in various cellular stresses. We investigated the
relations between PKR, eIF2α and BACE1 in AD brains in APP/PS1 knock-in mice and in hydrogen peroxide-
induced OS in human neuroblastoma (SH-SY5Y) cell cultures. Immunoblotting results showed that activated
PKR (pPKR) and activated eIF2α (peIF2α) and BACE1 levels are increased in AD cortices and BACE1 correlate
with phosphorylated eIF2α levels. BACE1 protein levels are increased in response to OS in SH-SY5Y cells and
speciﬁc inhibitions of PKR-eIF2α attenuate BACE1 protein levels in this model. Our ﬁndings provide a new
translational regulation of BACE1, under the control of PKR in OS, where eIF2α phosphorylation regulates
BACE1 protein expression.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Senile plaques, neuroﬁbrillary tangles, synaptic and neuronal loss
are salient neuropathological features of Alzheimer's disease (AD)
[1]. Senile plaques consist mainly of amyloid β (Aβ) peptides generat-
ed after APP (amyloid precursor protein) proteolysis by the amyloi-
dogenic pathway [2]. First, proteins possessing β-secretase activity
cut APP, shedding the ectodomain and leaving in the membrane a
fragment of 99 amino acids (C99) [3,4]. Afterwards, a γ-secretase
complex cleaves C99, generating an Aβ peptide. According to the am-
yloid hypothesis [5], the accumulation and aggregation of Aβ is the
trigger event leading to neurodegeneration in AD.eillissement Groupe Hospitalier
5010 Paris, France. Tel.: +33
Mouton-Liger).
rights reserved.BACE1 (beta-site APP cleaving enzyme 1) is expressed in neurons
and is responsible for most of the β-secretase activity in the central
nervous system [6,7]. Previous studies have shown that BACE1 levels
and activity are increased in postmortem AD brain samples [8-11],
suggesting that elevated BACE1 levels might play a pivotal role in
AD. BACE1 undergoes a complex set of post-translational modiﬁca-
tions during its maturation. The immature form is cleaved by mem-
bers of the Furin family of convertases [3]. This cleavage and the
extent of N-glycosylation on 4 sites are required for efﬁcient matura-
tion [12]. BACE1 gene expression is tightly regulated at the transcrip-
tion level by Sp1 [13] and STAT3 [14,15]. In AD brains, both normal
[11,16] or increased [17,18] BACE1 mRNA levels have been reported.
However, if a transcriptional regulation could not be completely ex-
cluded, most studies indicate that a post-transcriptional control is
mainly implicated in the increase of BACE1 detected in AD brains.
Various hypotheses have been proposed to explain how BACE1
might be post-transcriptionally regulated in response to aging or
pathological conditions including an alteration in speciﬁc microRNA
proﬁles [19,20] and a caspase-3-dependent inactivation of GGA3
(Golgi-associated, gamma adaptin ear containing, ARF binding
Table 1
This Table shows epidemiological and neuropathological characteristics of AD patients
and controls brains for immunoblotting. The number of the patients, sex, age, post-
mortem interval (PMI) and Braak stages are mentioned. Temporal cortex samples
were correspond to patients and controls labeled with *. NA: Not available.
Patients Age Sex PMI Braak
AD1* 79 F 3 6
AD2* 85 F 5 5
AD3 95 M 8 5
AD4* 92 F 17 5
AD5 87 M 7 5
AD6* 83 M 12 NA
AD7* 102 F 4 5
AD8* 73 F 6 6
AD9* 86 F 8 5
AD1O* 73 M 6 5
Control 1* 80 F 10 1
Control 2 84 F 7 2
Control 3 97 F 8 2
Control 4 93 F 6 2
Control 5* 82 M 5 2
Control 6* 78 F 12 1
Control 7* 69 F 11 1
Control 8* 69 M 5 2
Control 9* 59 F 4 2
Control 10* 86 M 9 1
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of BACE1 [21,22].
The double-stranded RNA-dependent protein kinase (PKR) is one
of the four mammalian serine-threonine kinases (the three others
being HRI (heme regulated inhibitor), GCN2 (general control non re-
pressed 2) and PERK (PKR-like endoplasmic reticulum kinase)) that
catalyzes the phosphorylation of the α subunit of eIF2 (eukaryotic
translation initiation factor-2) in response to stress signals, leading
to an inhibition of protein synthesis [23,24]. The activation of PKR is
induced by various triggers such as viral infection, calcium overload,
endoplasmic reticulum (ER) or oxidative stresses (OS) [25,26]. Recent
studies have indicated that dsRNA-independent activation may be
mediated by the overexpression of a direct activator: the human pro-
tein PACT (PKR ACTivating protein), or its mouse homologue, RAX
(PKR-associated protein X) [27-30]. In AD brains, previous reports
have shown that phosphorylated PKR is increased in neuronal cyto-
plasm and nuclei, in granulovacuolar degenerations, as well as around
senile plaques [31,32]. Our previous study in 2002 has also demon-
strated that phosphorylation of eIF2α could play an essential role in
AD neurodegeneration [33]. These results suggest that PKR-induced
cellular stress could contribute to neurodegeneration in AD [34].
PKR could be also involved in the mechanism of tau phosphorylation
via Glycogen synthase kinase 3β (GSK-3β) phosphorylation [35].
Recently, a study has shown that energy deprivation induced
PERK activation, the phosphorylation of eIF2α and an increased
BACE1 translation [36]. Similarly, in the brains of the transgenic
mouse 5XFAD with human APP mutation and an aggressive amyloid
pathology, phosphorylation of eIF2α increases BACE1 levels and the
abilities to control Aβ accumulation during the course of disease pro-
gression [37]. These alterations of BACE1 mRNA translational control
by eIF2α could be explained by a stress-dependent phenomenon of
translation initiation. The BACE1 mRNA 5′-untranslated region
(5'UTR) acts as a translational repressor, characteristics shared with
many 5′UTRs of transcripts that are translationally controlled by cel-
lular stress, such as huntingtin [38] and transcription factors [39,40].
The presence of long, G-C-rich, upstream open reading frames
(uORFs) in the 5′UTR is thought to down-regulate the efﬁciency of
translation initiation of the main BACE1 ORF [41-43].
Post-mortem observations of AD brains provided strong evidences
for increased levels of cellular OS [44-47]. There is also a signiﬁcant
correlation between BACE1 activity and oxidative markers in sporadic
AD brains [48]. Previously, the activation of c-jun N-terminal kinase/
activator protein 1 (JNK/AP1) pathway was proposed to explain the
BACE1 mRNA increase detected under OS [49]. However, little is
known about the translational control of BACE1 in OS condition. The
goal of this study was to assess the role of PKR in BACE1 protein ex-
pression during OS. Our results showed that pPKRThr446/PKR and
peIF2αSer51/peIF2α ratios and BACE1 levels are increased in AD brains
and in APP/PS1 mouse brains. Furthermore, in neuroblastoma cells,
OS induces the PKR-eIF2α pathway, and leads to an increase of
BACE1 protein level. Moreover, the speciﬁc inhibition of PKR by
chemical inhibition or by siRNA signiﬁcantly attenuates BACE1 level
in this cellular model.
2. Materials and methods
2.1. Human brains
For all human brains, consents were obtained for using postmor-
tem tissues. The post-mortem intervals (PMI) never exceeded
24 hours. Assessment of pathology associated with dementia was
performed by examining histological sections of frontal, temporal, pa-
rietal and occipital lobes, corpus striatum, thalamus, midbrain, pons,
medulla and cerebellum. Selected sections were immunostained for
Aβ, tau and α-synuclein. All these patients had a history of progres-
sive dementia and satisﬁed National Institute of Neurological andCommunicative Disorders and Stroke–Alzheimer's Disease and Relat-
ed Disorders (NINCDS-ADRDA) criteria for probable AD and satisﬁed
neuropathologic criteria for AD according the CERAD protocol.
For immunoblotting analysis, frozen brain samples of frontal cor-
tex from 10 AD patients and 10 age-matched controls and temporal
cortex from 8 AD and 7 age-matched controls were provided by the
Department of Neuropsychiatry, University of Geneva, Geneva, Swit-
zerland (Pr Constantin Bouras) (Table 1).
2.2. Mouse brains
All animal experiments were performed in accordance with the
guidelines of the French Agriculture and Forestry Ministry for han-
dling animals (decree 87849, license A75-05-22). All transgenic
mice and littermate were provided by Sanoﬁ. This APP/PS1 knock-in
(APP/PS1 KI) transgenic mouse model carries M233T/L235P
knocked-in mutations in presenilin-1 and overexpresses mutated
human Aβ amyloid precursor protein Aβ x-42 is the major form of
Aβ species present in this model with progressive development of a
complex pattern of N-truncated variants and dimers, similar to
those observed in AD brain. Furthermore, at 10 months of age, they
display an extensive neuronal loss (>50%), which is already detect-
able at 6 months of age [50].
For brain preparation, three mice per genotype were anaesthe-
tized with pentobarbital (40 mg/kg, i.p.) and received an intracardial
perfusion with cold PBS. Brains were removed and dissected then
placed in 4% (w/v) paraformaldehyde in PBS for immunohistochemis-
try. Brains homogenates of 9 months old transgenic mice APP/PS1 KI
(n=6) and 4 age-matched wild type were established as described
in a previous report [50].
2.3. Cell cultures
SH-SY5Y human neuroblastoma cells, obtained from the ATCC,
were maintained at 37 °C under 5% CO2/95% humidiﬁed air incubator
in completed media with 45% Minimum Essential Media (MEM)
(Invitrogen, Carlsbad, CA, USA) 45% Ham's F-12 medium (Invitrogen),
10% inactivated fetal bovine serum, enriched with 2 mM L-glutamine,
1 mM non essential amino acid (Invitrogen), 1 mM sodium pyruvate
(Invitrogen), 100 U/ml penicillin and 100 mg/ml streptomycin
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treated with different chemical compounds.
2.4. Cell treatment
To induce oxidative stress, the cells were treated with hydrogen
peroxide (H2O2) (Calbiochem, Darmstadt, Germany) at the concen-
trations 0.2 mM, and 0.5 mM from 30 minutes to 16 hours.
To inhibit the activation of PKR, cells were pretreated 1 hour be-
fore H2O2 exposure with PRI (peptide PKR inhibitor). PRI is coupled
to a penetratin and can bind to the double-stranded RNA binding
site of PKR and prevent its activation (NeoMPS Polypeptide Laborato-
ries, Strasbourg, France) at various concentrations (50 to 100 μM).
Due to the short-time effect, PRI treatments were repeated every
hour.
The small-molecule drug salubrinal (Calbiochem) selectively
blocks dephosphorylation of eIF2α by inhibiting the PP1 (Protein
Phosphatase 1)/GADD34 (Growth Arrest and DNA Damage-
Inducible Protein 34) complex formation [51]. Salubrinal was added
to the cell media at 100 mM, 24 hours before stress exposure.
Cycloheximide (Chx) (Sigma, St. Louis, MO, USA), a protein syn-
thesis inhibitor that acts speciﬁcally on the 60S subunit of eukaryotic
ribosomes was used at 10 μg/ml to block protein synthesis in SH-
SY5Y cells. To block transcription, Actinomycin D (ActD) (Calbio-
chem), an antineoplastic antibiotic known to act as a speciﬁc inhibitor
of DNA-dependent RNA synthesis, was added to the cell media at
1 mg/ml. Finally, to selectively inhibit the proteasome, cells were pre-
treated with Lactacystin (Lact) (10 μM) (Sigma). When necessary,
control cells were treated with DMSO.
2.5. Cell transfection
To selectively inhibit the PACT-PKR pathway, SH-SY5Y cells were
transfected either with Short hairpin (Sh) RNA to PACT or silencing
(si) RNA to PKR. Control (scrambled) siRNA (ScrPKR) and siRNA toFig. 1. Compared levels of pPKRThr446, PKR full, peIF2αSer51, eIF2α full, BACE1 and amyloid β
noblot analysis of pPKRThr446, PKR full, peIF2αSer51, eIF2α full and BACE1 in AD and control
poral cortex samples. C. Histograms showing that pPKRThr446/PKR ratio, peIF2αSer51/eIF2α
D. peIF2αSer51/eIF2α ratio is correlated to BACE1 level but not to amyloid β in frontal cortePKR (5′-GCAGGGAGUAGUACUUAAAUAUU-3′) (SiPKR) were synthe-
sized by Dharmacon Research, Inc. (Lafayette, CO, USA). The siRNAs
(ﬁnal concentration 25 nM) were transfected for 48 hours using
FuGENE HD (Roche, Penzberg, Germany) before any treatment.
ShRNA of PACT (ShPACT) (5′-GAACCAGCUUAAUCCUAUU-3′) and
scrambled (ScrPACT) were transfected into SH-SY5Y cells using Lipo-
fectamine 2000 (Invitrogen) for 48 hours before any treatment.2.6. Tissue and cell extracts
Cortices were homogenized with a Potter in Laemmli sample buff-
er 1:10 (wt/vol) containing 5% sodium dodecyl sulfate (SDS), prote-
ase and phosphatase inhibitors cocktail. The lysate was sonicated
and then centrifuged at 15,000g for 15 minutes at 4 °C.
To prepare cell lysates for immunoblotting, cells were rapidly
washed in phosphate-buffered saline (PBS) and then lysed in a
radio immune precipitation assay buffer (RIPA buffer) containing
25 mM β-glycerophosphate, 50 mM sodium ﬂuoride, 2 mM sodium
pyrophosphate, protease inhibitors (Roche), 1 mM sodium orthova-
nadate, and 0.1 mM calyculin (Sigma) as phosphatase inhibitors.
They were sonicated and centrifuged at 20,000g for 10 minutes. The
protein concentration in the supernatant was determined with
Micro BCA Protein Assay Reagent Kit (Thermo scientiﬁc, Cergy-
Pontoise, France) using the manufacturer's protocol.2.7. Antibodies and immunoblot analysis
Protein samples (20 to 30 μg for brains samples, 50 μg for cell sam-
ples) separated on 4–12% (or on 12%) NuPAGE Bis-Tris gels (Invitro-
gen) and then electroblotted onto nitrocellulose membranes (GE
Healthcare, Chalfont St. Giles, UK) at 400 mAmps per gel in 25 mM
Tris, (pH 8.3), 200 mM glycine and 20% ethanol. After protein trans-
fer, nitrocellulose membranes were blocked in 5% milk in TBS, and
then incubated with primary antibody.in post-mortem temporal cortex of AD patients (n=8) and controls (n=7). A. Immu-
temporal cortex samples. B. Immunoblot analysis of amyloid β in AD and control tem-
ratio, and BACE1, normalized on tubulin level, are increased in AD temporal cortex.
x samples. *pb0.05, **pb0.01, ***pb0.001.
Fig. 2. Levels of pPKRThr446, PKR full, peIF2αSer51, eIF2α full, BACE1 and amyloid β in post-mortem frontal cortex of AD patients (n=10) and controls (n=10). A. Immunoblot
analysis of pPKRThr446, PKR full, peIF2αSer51, eIF2α full and BACE1 in AD and control frontal cortex samples. B. Immunoblot analysis of amyloid β in AD and control frontal
cortex samples. C. Diagram representations showing that pPKRThr446/PKR ratio, peIF2αSer51/eIF2α ratio and BACE1, normalized on tubulin level, are signiﬁcantly increased
in AD frontal cortex. D. Graphic representation that illustrates a signiﬁcant correlation between peIF2αSer51/eIF2α ratio and BACE1 and amyloid β levels. *pb0.05,
**pb0.01, ***pb0.001.
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β (Millipore, Billerica, MA, USA), Rabbit anti-BACE1 (Santa Cruz, Dan-
vers, MA, USA), rabbit anti-phosphorylated PKRThr446 (pPKRThr446)
(Santa Cruz), rabbit anti-PKR (Cell Signaling, Beverly, MA, USA),
goat anti-PACT (Santa Cruz), rabbit anti-phosphorylated PERKThr981
(pPERKThr981) (Santa Cruz), rabbit anti-PERK (Santa Cruz), rabbit
anti-phosphorylated eIF2αSer51 (peIF2αSer51) (Cell Signaling), rabbit
anti-eIF2α (Cell Signaling), mouse anti-Tubulin (Santa Cruz).
IR Dye 700DX conjugated anti-mouse IgG, IR Dye 800CW conju-
gated anti-goat IgG and IR Dye 800CW conjugated anti-rabbit IgG
(Rockland Immunochemical Inc., Gilbertsville, PA, USA) were used
as secondary antibodies.Fig. 3. Expression of pPKRThr446, peIF2αSer51 and BACE1 in post-mortem APP/PS1 KI mice and
peIF2αSer51 and BACE1 were increased compared to wild type brains. B. Diagram representa
in APP/PS1 KI mice.Bound proteins were visualized with the Odyssey Imaging System
(Li-Cor Biosciences, Lincoln, NE, USA) and quantiﬁed with Multigauge
software (Fuji ﬁlm, Tokyo, Japan).
2.8. Quantitative RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) from SH-
SY5Y cells. SuperScript II reverse transcriptase kit (Invitrogen) with
random decamer priming was used to synthesize the ﬁrst strand
cDNA from samples with an equal amount of total RNA (1 μg), accord-
ing to the manufacturer's instructions. cDNA samples were forwarded
to ampliﬁcation with speciﬁc primers for PKR, BACE1 and GAPDHlittermates (WT). A. Immunoblotting studies of mouse brains showed that pPKRThr446,
tions show that pPKRThr446/PKR ratio, peIF2αSer51/eIF2α ratio, and BACE1 are increased
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Mx3005P PCR cycler (Agilent Technologies, Massy, France). Human
BACE1 primers [forward 5′-GCAGGGCTACTACGTGGAGA-3′ and re-
verse 5′-GTATCCACCAGGATGTTGAGC-3′], human GAPDH primers,
[forward 5′-AATCCCATCACCATCTTCC-3′ and reverse 5′-GGACTCCAC-
GACGTACTCA-3′] and human PKR primers [forward 5′-GGCACCCA-
GATTTGACCTTC-3′ and reverse 5′-TCCTTGTTCGCTTTCCATCA-3′]
were used in the present studies.
cDNA ampliﬁcation was carried out as follows: denaturation at
94 °C for 2 minutes, followed by 35 cycles of denaturation at 94 °C
for 15 seconds, primer annealing at 62 °C for 30 seconds, and exten-
sion at 72 °C for 40 seconds. A ﬁnal extension was carried out atFig. 4. Oxidative stress induced by H2O2 exposure in SH-SY5Y cells increases PKR, and eIF2
eight different antibodies speciﬁc for pPKRThr446, PKR full, pPERKThr981, PERK, peIF2αSer51
time course enhancement relative to Tubulin level, respectively of pPKRThr446/PKR ratio (B)
posure. n=5 for each condition. *pb0.05, **pb0.01, ***pb0.001.72 °C for 10 minutes, ending with a 4 °C hold cycle. All assays were
performed in triplicate, and BACE1 and PKR mRNA levels were nor-
malized with the expression levels of GAPDH. Relative levels and
gene copy numbers were calculated using the deltaCp method, as de-
scribed by Pfafﬂ [52].
2.9. Statistical analysis
Statistical analysis was performed using GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, CA 92037 USA). Results were con-
sidered signiﬁcant when pb0.05 using a non-parametric Mann and
Whitney test. The correlation between PKR, BACE1 and eIF2α levelsα activations and BACE1 levels. Western blot of SH-SY5Y proteins extract revealed by
, eIF2α full, BACE1 and tubulin. B–E. Histogram representation showing progressive
, pPERKThr981/PERK ratio (C), peIF2αSer51/eIF2α ratio (D), and BACE1 (E) after H2O2 ex-
890 F. Mouton-Liger et al. / Biochimica et Biophysica Acta 1822 (2012) 885–896in cortical samples was assessed using Spearman correlation coefﬁ-
cients, in AD patients and control brains.
3. Results
3.1. Signiﬁcant correlation between BACE1 levels and eIF2α activation in
human AD brains
Immunoblot analysis of Fig. 1 revealed a statistically signiﬁcant in-
crease of amyloid β, BACE1 levels and peIF2αSer51/eIF2α ratio (60%)
in AD (n=8) versus control temporal cortices (n=7) (Fig. 1A–B).
Linear regression analysis showed a signiﬁcant correlation between
peIF2αSer51/eIF2α ratio and BACE1 levels, but not with amyloid β
(Fig. 1D). We also assessed the activation of PKR in the temporal cor-
tex, by measuring pPKRThr446/PKR ratio. PKR activation was increased
in temporal AD cortices (30.7%) (Fig. 1A and C). The variations of
phosphorylated forms of PKR and eIF2α proteins are correlated
(data not shown), but linear regression method did not reveal a sig-
niﬁcant correlation between pPKRThr446/PKR ratio and BACE1 level
(Fig. 1C).
In frontal cortex of AD patients (n=10), we also found increased
eIF2α activation (112%), compared to controls (n=10) (Fig. 2A–C).
These levels were signiﬁcantly correlated in controls and AD patientsFig. 5. Inhibition of PKR during H2O2-induced stress decreases eIF2α activation and BACE1
pPKRThr446, PKR full, pPERKThr981, PERK full, peIF2αSer51, eIF2α full, BACE1 and tubulin. B–D.
(C), and BACE1 (D), normalized on Tubulin level, in SH-SY5Y treated with H2O2 (0.5 mM)
*pb0.05, **pb0.01, ***pb0.001.with BACE1 levels (75%) and with amyloid β (Fig. 2B–D). Nevertheless,
no signiﬁcant correlationwas observed between PKR activation (31.8%)
(Fig. 2A and C) and BACE1 levels or amyloid β (data not shown).
3.2. Increases of BACE1 levels and eIF2α activation in APP/PS1-KI
Comparable analyses were performed in the APP/PS1 KI mice pre-
viously characterized by widespread neuronal degeneration and
pPKR accumulation [53]. Molecular evaluations revealed increased
pPKRThr446/PKR and peIF2αSer51/peIF2α ratios, respectively 39.6%
and 58.4% (Fig. 3A and B) in APP/PS1 KI mice compared to control
mice. In addition, the levels of BACE1 in transgenic mice were also in-
creased by 43.2% (Fig. 3A and B). However, statistical analyses did not
reveal signiﬁcant correlation between PKR and eIF2α activation and
BACE1 levels in this model.
3.3. OS induces an increase of PKR level and activation in SH-SY5Y cells
To assess in vitro if OS exposure could reproduce human ﬁndings,
we treated neuroblastoma cells with H2O2 and analyzed by immuno-
blot PKR, pPKRThr446, eIF2α, peIF2αSer51, PERK, pPERKThr981 and
BACE1 levels. In these cell extracts, a progressive enhancement of
pPKRThr446/PKR and peIF2αSer51/eIF2α ratio (Fig. 4A–B and D) waslevel. A. Western blot of SH-SY5Y proteins revealed by different antibodies speciﬁc for
Quantiﬁcation of the relative level of pPKRThr446/PKR ratio (B); peIF2αSer51/eIF2α ratio
and PRI (50 μM or 200 μM), compared to control cells (DMSO). n=5 for each group.
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2 hours (respectively a 1.93 and 2.82 fold increase), and this changes
were not anymore observed after 4 hours of treatment. In contrast,
pPERKThr981/PERK ratio was unchanged (Fig. 4A and C). Finally, a
transient increase of BACE1 level was detected with various concen-
trations of H2O2 (Fig. 4E). Notably, signiﬁcant increases of BACE1
were found for the mature form of the protein. Immature forms of
the protein have not been detected by our immunoblot approach.
We therefore only present data for the mature BACE1 in ﬁgures and
immunoblot analyses.
Moreover, in SH-SY5Y cells, PKR protein level progressively
increased with 0.2 mM and 0.5 mM H2O2 treatment, reaching a
maximum (+58.3%) at 2 hours (Suppl. Fig. 1A). Quantitative RT-
PCR conﬁrmed that OS leads to signiﬁcant increase of PKR mRNA
expression at 1 and 2 hours, respectively 32.3% and 26.8% (Suppl.
Fig. 1B).
3.4. PKR inhibition reduces eIF2α activation and BACE1 level
To test if under OS condition PKR could control eIF2α phosphory-
lation and BACE1 expression, we pretreated SH-SY5Y cells with PRI, a
speciﬁc inhibitor of PKR activation (Fig. 5). Using immunoblot analy-
sis, we showed that PRI inhibits PKR activation in physiological condi-
tions and partially reversed OS effect on pPKRThr446/PKR ratios after
H2O2 exposure (30 minutes and 2 hours) (Fig. 5A–B). PRI did not af-
fect PERK activation. PRI addition also signiﬁcantly inhibited eIF2α
activation, induced by H2O2, starting after 30 minutes of treatment
(Fig. 5A and C). BACE1 expression was also reduced by PRI after
2 hours of H2O2 exposure, indicating that PKR could control BACE1
levels during OS (Fig. 5A and D).
To conﬁrm these results, we evaluated the effect of PKR siRNA
(SiPKR) in our system. SH-SY5Y cells transfected with SiPKR were ex-
posed to 0.5 mM of H2O2. Immunoblot analysis (Fig. 6A), showed a
reduction of PKR, peIF2αser51/eIF2α ratio and BACE1 level in SiPKR-Fig. 6. Effect of H2O2 treatment on PKR, PACT, eIF2α, and BACE1 expression in wild type SH
revealed by different antibodies speciﬁc for pPKRThr446, PKR full, PACT, peIF2αSer51, eIF2α
(C) in SH-SY5Y transfected with SiPKR, ShPACT or their relative scramble sequence show
each group of cells. *pb0.05, **pb0.01, ***pb0.001.transfected cells compared with non-transfected cells or in cells
transfected with a scramble siRNA-negative control of PKR (ScrPKR)
(Fig. 6B–C).
To determine the implication of the PKR activator (PACT) in this
regulatory pathway, we also used short-hairpin RNA of PACT. West-
ern blot experiments on SH-SY5Y cells transfected with ShPACT
revealed that the inhibition of PACT expression, attenuated BACE1
level enhancements (−20%) induced by OS (Fig. 6B–C). These ﬁnd-
ings add gene expression evidence that the PACT-PKR pathway can
regulate BACE1 expression levels in our cell culture models.
3.5. Activation of eIF2α is implicated in OS-induced BACE1 increase
Correlation observed in frontal and temporal cortices between
peIF2αSer51/eIF2α ratio and BACE1 suggest that BACE1mRNA transla-
tion could be enhanced by eIF2α activation. To directly test this hy-
pothesis, we exposed neuroblastoma cells, 24 hours before H2O2
treatment, to salubrinal (Sal), a drug which increases phosphorylated
eIF2α (Fig. 7). As expected, Sal treatment leads to a signiﬁcant in-
crease (30.7%) of peIF2αSer51/eIF2α ratio in OS condition (Fig. 7C).
BACE1 levels induced by OS, were also increased (+20.2%) by salu-
brinal exposure (Fig. 7D), whereas PKR activation was not modiﬁed
by salubrinal (Fig. 7B).
3.6. OS-induced BACE1 increases at transcriptional and translational
levels
To determine if translational regulation by the PKR-eIF2α path-
way is the only cause of OS-induced BACE1 elevation, we successively
exposed cells to inhibitors of translation, transcription, and proteaso-
mal activity during OS.
Firstly, we validated our hypothesis for the translational control of
BACE1 under OS by treating SH-SY5Y cells with cycloheximide, an in-
hibitor of protein biosynthesis. After 2 hours of Chx treatment, BACE1-SY5Y cells, or transfected with SiPKR or ShPACT. A. Western blot of SH-SY5Y proteins
full, BACE1 and Tubulin. B–C. Relative levels of peIF2αSer51/eIF2α ratio (B) and BACE1
ed that PACT-PKR pathway can regulate eIF2α activation and BACE1 level. n=3 for
Fig. 7. Salubrinal induces signiﬁcant increase of BACE1 expression in SH-SY5Y cells treated with H2O2. A. Western blot of SH-SY5Y cells proteins with speciﬁc antibodies for pPKRThr446,
PKR full, peIF2αSer51, eIF2α full, BACE1 and Tubulin. B–D. Effect of salubrinal on pPKRThr446/PKR ratio (B); peIF2αSer51/eIF2α ratio (C), and BACE1 level (D) in SH-SY5Y cells treated or not
with H2O2 (0.5 mM). All values were normalized on Tubulin level. n=4 for each group. *pb0.05, **pb0.01, ***pb0.001.
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reversed by salubrinal.
Secondly, we treated neuroblastoma cells with actinomycin D.
Transcriptional inhibition decreased BACE1 level in our system
(Fig. 8A and C), suggesting that a transcriptional action occurs in the
control of BACE1 modulation.
To conﬁrm the transcriptional regulation of BACE1 in this
model, we conducted quantitative RT-PCR on BACE1 mRNA. We
found that BACE1 messages were increased during OS (Fig. 8D).
One hour of H2O2 treatment upregulates BACE1 mRNA levels in
SH-SY5Y. The addition of PRI did not signiﬁcantly affect this
increase (Fig. 8D).
Thirdly, we tested if BACE1 protein stability could be modulated
by the ubiquitin–proteasomal degradation pathways. Combined
treatment of the SH-SY5Ywith H2O2 and lactacystin, a proteasome in-
hibitor, did not reveal any modiﬁcation of activated eIF2α or BACE1
levels (Fig. 8A and C).
4. Discussion
This study shows that the phosphorylated forms of PKR and eIF2α
as well as the levels of BACE1 are signiﬁcantly increased in AD cortical
regions compared to control subjects as well as in APP/PS1 KI mice.
Moreover in these areas, BACE1 and activated eIF2α levels are corre-
lated, suggesting a possible signaling interaction between these pro-
teins in degenerating brains. In addition, our results revealed that
PKR activation, during OS, can regulate BACE1 protein levels in
human neuroblastoma cells.
The ﬁrst question to be addressed is how PKR, eIF2α and BACE1
are linked in human brains. Previous studies have shown that these
proteins are expressed in human cortical neurons [54]. In addition,
we demonstrated a correlation between peIF2αSer51 and BACE levelsin frontal and temporal cortex areas, and a correlation between
peIF2αSer51 and amyloid β levels in frontal cortex. The lack of correla-
tion between activated PKR and BACE1 could be explained by three
possibilities. 1) The presence of three other identiﬁed kinases, PERK,
HRI and GCN2, able to independently regulate eIF2α in response to
various cellular stresses [23,24]. For example, PERK, component of
the unfolded protein response, plays a critical role in the ER stress
response observed in AD [55,56] and could enhance eIF2α phosphor-
ylation in AD brains. 2) The control of BACE1 levels could take place
during translation but also, by miRNA, a molecular phenomenon
that are not under PKR control [19,22,57]. 3) Another factor is that ac-
tivated PKR is prone to induce cell degeneration [58]. BACE1 levels
could be modiﬁed during this detrimental cellular process. Neverthe-
less, PKR could partly inﬂuence BACE1 levels and thus amyloid β pro-
duction in human brains.
In patients with AD, the rate of oxidative products is related to
cerebral damage, and ample human and experimental evidences
support the importance of OS in the pathogenesis of this disease
[44-46,48]. Our ﬁndings demonstrated that phosphorylated PKR
on threonine 446 is increased in OS condition with a transient acti-
vation from 30 minutes to 4 hours under H2O2 exposure, leading to
an enhanced pPKRThr446/PKR ratio (Fig. 4A–B). In SH-SY5Y cells, a
progressive enhancement of peIF2αSer51/eIF2α ratio and BACE1
levels was also detected. In parallel, pPERKThr981/PERK ratio re-
mains unchanged, indicating that eIF2α activation and BACE1 in-
crease occurs independently of PERK activation in OS. These
results concerning PKR are reminiscent of those observed in AD
brains and tend to validate the fact that over-activation of PKR
could induce detrimental consequences in affected cells.
Moreover, increase levels of PKRmRNA and PKR protein were also
observed in SH-SY5Y after OS exposure (Suppl. Fig. 1A-B), as previ-
ously described in Jurkat T cells [26]. The exact mechanisms
Fig. 8. Role of transcriptional, translational and proteasomal activity on BACE1 increase in OS condition. A. Effect of Actinomycin D (Act D), Cycloheximide (Chx) and Lactacystin (Lact) on
BACE1 protein expression were investigated by western-blot of SH-SY5Y cells proteins with speciﬁc antibodies for pPKRThr446, PKR full, peIF2αSer51, eIF2α full, BACE1 and Tubulin. B–C.
Quantiﬁcation of peIF2αSer51/eIF2α ratio (B), and BACE1 level (C) in SH-SY5Y cells treatedwith H2O2 and several inhibitors. Both levels normalized on Tubulin increased with both Act D
and Chx treatments, while nomodiﬁcationwas observed after Lact exposure. Results were obtained from 3 independent experiments. *pb0.05, **pb0.01, ***pb0.001. D. Effect of OS and
PRI on BACE1mRNA levels, assessed with qRT-PCR. BACE1mRNA levels were normalized to GAPDH mRNA levels, n=4 for each condition, ns=non signiﬁcant.
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it is already known that basal PKR, PACT and BACE1mRNAs expression
could be modulated by OS-induced transcription factor Sp1 [59,60].
Further experimental studies by quantitative expression assays,
using Sp1 inhibitors such as mithramycin will be necessary to conﬁrm
a possible transcriptional control of these transcripts under OS
condition.
Our results in SH-SY5Y cells also show that PKR inhibition, carried
out with pharmacological agents (PRI) or PKR siRNA, can modulate
eIF2α phosphorylation and BACE1 levels (Fig. 5 and 6). The linear re-
lation between BACE1 expression and β-secretase activity [61] sug-
gests that amyloid β production could be also modulated in similar
proportions by PKR inhibition. Modulation of eIF2α activationobtained in this study with the cell-permeable peptide PRI are com-
parable to previous published data in which PRI could afford neuro-
protection in a similar cell culture system [53]. In addition, PKR
inhibition is able to attenuate tau phosphorylation in SH-SY5Y cells,
induced by Aβ or the ER stress inducer tunicamycin [35]. In the fu-
ture, PKR could represent an interesting target to modulate BACE1
levels and tau phosphorylation [35,62].
Previous reports suggest that PACT may be part of the PKR activa-
tion process detected in neurons [29]. We have shown here that
transfected cells with ShPACT expressed attenuated levels of both
peIF2αSer51/eIF2α ratio and BACE1, indicating that: i—PKR activation
is controlled by PACT in OS condition; ii—PACT levels via PKR activa-
tion could modulate BACE1 level and activity after H2O2 exposure.
Fig. 9. Representative diagram of BACE1 regulation by PKR and eIF2α in response to
oxidative stress.
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expression could be enhanced in AD brains or by various cell stresses,
such as ER stress [29,63,64].
Our ﬁndings also indicated that BACE1 is regulated by a transla-
tional mechanism initiated by the PACT/PKR pathway (Fig. 7). The re-
cent literature provides strong evidences that translation, in
particular the initiation step, is a highly regulated process that
plays a critical role in the cellular response to stress, and in neurode-
generation. Phosphorylation of eIF2α at Ser51 is a major mechanism
for regulation of translation initiation in response to various cellular
stresses [55,65]. This phosphorylation usually suppresses general
translation [66], but selectively stimulates the translation of stress re-
sponse transcript, that contain in their 5’ UTR region, inhibitory
uORFs [40,67]. A very recent study also conﬁrms this potential role
of PKR on BACE1. Activation of PKR by herpes simplex virus type 1
or dsRNA analog poly (I:C) causes Aß accumulation via de-
repression of BACE1 translation [68].
However, if we have clearly indentiﬁed a translational pathway
that implicates PKR/eIF2α in OS, the exact role of the different
BACE1 uORFs in this regulation needs to be further evaluated
[65,69].
Actinomycin D treatment in SH-SY5Y cells has revealed that,
during OS, a transcriptional control is also implicated in the regula-
tion of BACE1 levels. RT-PCR analyses of BACE1 expression also con-
ﬁrmed the transcriptional part in BACE1 modulation by OS (Fig. 8).
This is consistent with several recent studies showing that JNK and
extracellular signal regulated MAP kinase (ERK) could modulate
BACE1 transcription and promote amyloid β production during ex-
perimental OS [49,70,71]. Several works have shown that PKR acts
upstream of JNK and may control its activation in cells treated by vi-
ruses [72,73] or other stresses (ribotoxic stress and DNA damage re-
sponse) [74,75].Taking together, our ﬁndings provide a new inter-related tran-
scriptional and translational regulation of BACE1 expression, under
the control of PKR. We can suggest here, as already proposed for the
DNA damage response [74], a model of bipartite BACE1 protein ex-
pression in response to oxidative stress including activation of
PACT-PKR pathway and eIF2α translational control and as well as a
transcriptional regulation mediated by c-jun terminal kinase
(Fig. 9). Further studies will be needed to evaluate in vitro the role
of PKR in Aβ production.
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